Drugs / BAY2965501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05614102 | Nov 2022 → Jul 2026 overdue | cancer | Bayer | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 2965501 | “Here participants will receive BAY 2965501 in combination with pembrolizumab and platinum based chemotherapy.” NCT05614102 ↗ |
| Action | Inhibit | “BAY2965501 blocks an enzyme in T-cells to activate them.” NCT05614102 ↗ |
| Route | Oral | “All participants will take BAY2965501 by mouth.” NCT05614102 ↗ |